NCT02128269View on ClinicalTrials.gov

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Antiphospholipid (aPL)-Positive
Interventions
BIOLOGICAL

Study Drug- ALXN1007

10 mg/kg IV q 2 weeks x 12 doses

Trial Locations (9)

10021

Hospital for Special Surgery, New York

22030

O & O Alpan, LLC, Fairfax

35128

Azienda Ospedaliera di Padova, Padua

59037

Hopital Claude Huriez - CHU Lille, Lille

75679

Hôpital Cochin, Paris

77555

University of Texas Medical Branch, Galveston

05403-000

Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo

060-8648

Hokkaido University Hospital, Sapporo

NW12PG

University College London Hospitals, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY